Why is Shukra Pharmaceuticals Ltd ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.66 times
2
Healthy long term growth as Operating profit has grown by an annual rate 97.78%
3
With a growth in Net Sales of 87.93%, the company declared Very Positive results in Sep 26
- The company has declared positive results for the last 4 consecutive quarters
- PAT(Latest six months) Higher at Rs 25.67 cr
- NET SALES(Q) Highest at Rs 44.20 cr
4
Stock is technically in a Bullish range
- The technical trend has improved from Mildly Bullish on 28-Sep-26 and has generated 41.73% returns since then
- Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and DOW
5
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 0.53% over the previous quarter and collectively hold 0.65% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
How much should you buy?
- Overall Portfolio exposure to Shukra Pharma. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Shukra Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shukra Pharma.
101.8%
1.31
77.89%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
51.13%
EBIT Growth (5y)
97.78%
EBIT to Interest (avg)
16.49
Debt to EBITDA (avg)
0.66
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.85
Tax Ratio
27.55%
Dividend Payout Ratio
4.57%
Pledged Shares
0
Institutional Holding
0.65%
ROCE (avg)
11.39%
ROE (avg)
19.13%
Valuation Key Factors 
Factor
Value
P/E Ratio
84
Industry P/E
40
Price to Book Value
44.12
EV to EBIT
55.62
EV to EBITDA
52.45
EV to Capital Employed
44.59
EV to Sales
32.92
PEG Ratio
0.24
Dividend Yield
0.01%
ROCE (Latest)
80.17%
ROE (Latest)
58.82%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
No Trend
Technical Movement
25What is working for the Company
PAT(Latest six months)
Higher at Rs 25.67 cr
NET SALES(Q)
Highest at Rs 44.20 cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Shukra Pharma.
Profit After Tax (PAT) - Latest six months
At Rs 25.67 cr has Grown at 652.79%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 44.20 cr has Grown at 136.2% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 18.71 CrMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
Higher at Rs 25.67 cr
than preceding 12 month period ended Sep 2026 of Rs 22.05 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 44.20 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)